(firstQuint)An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease.

 IPX066 is intended for chronic treatment of motor symptoms for all stages of PD.

 This study is designed to enroll subjects who have successfully completed one of the following studies of IPX066: - IPX066-B08-05 (A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disease) - IPX066-B08-11 (A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa - Levodopa) - IPX066-B09-02 (A Study to Evaluate the Safety and Efficacy of IPX066 in Advanced Parkinson's Disease) All participants will be given IPX066 for 9 months.

.

 An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease@highlight

The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.

